PMID- 38187185
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240109
IS  - 2192-3183 (Electronic)
IS  - 2192-3183 (Linking)
VI  - 13
IP  - 1
DP  - 2024 Jan
TI  - Potential drug interactions between pazopanib and proton pump 
      inhibitors/potassium-competitive acid blockers in patients with soft tissue 
      sarcoma.
PG  - 63-67
LID - 10.1007/s13691-023-00638-2 [doi]
AB  - Because absorption of the oral drug pazopanib depends on gastric pH, concomitant 
      use of proton pump inhibitors (PPIs)/potassium-competitive acid blockers (P-CABs) 
      may inhibit pazopanib absorption by elevating the gastric pH. This study 
      investigated to what extent the concomitant use of PPIs/P-CABs affects treatment 
      with pazopanib in patients with soft tissue sarcoma. We retrospectively reviewed 
      the medical records of patients with soft tissue sarcoma who had received at 
      least one dose of pazopanib at our institution, among which those who had 
      received concomitant PPIs/P-CABs were included in this analysis. Using paired 
      sample t tests, the frequency of dose reduction or interruption of pazopanib and 
      the major adverse events (AEs) were compared in each patient between periods with 
      and without PPIs/P-CABs. Between January 2018 and December 2022, eight patients 
      were eligible. The median time to treatment failure (TTF) was 3.9 months 
      (2.1-38.2 months). Two patients received concomitant PPIs/P-CABs throughout their 
      treatment with pazopanib. Among the other six patients, dose reduction or 
      interruption of pazopanib occurred less frequently (P = 0.021), and neutropenia 
      tended to be milder (P = 0.155) with the concomitant use of PPIs/P-CABs. Although 
      the concomitant use of PPIs/P-CABs had no apparent effect on TTF in patients 
      undergoing pazopanib treatment, dose reduction or interruption of pazopanib 
      occurred less frequently, and neutropenia was milder, suggesting that concomitant 
      use of PPIs/P-CABs might decrease the pharmacological activity of pazopanib. 
      SUPPLEMENTARY INFORMATION: The online version contains supplementary material 
      available at 10.1007/s13691-023-00638-2.
CI  - (c) The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 
      2023. Springer Nature or its licensor (e.g. a society or other partner) holds 
      exclusive rights to this article under a publishing agreement with the author(s) 
      or other rightsholder(s); author self-archiving of the accepted manuscript 
      version of this article is solely governed by the terms of such publishing 
      agreement and applicable law.
FAU - Liang, Yao
AU  - Liang Y
AD  - Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 
      Nagoya, Aichi 466-8560 Japan. ROR: https://ror.org/008zz8m46. GRID: 
      grid.437848.4. ISNI: 0000 0004 0569 8970
FAU - Maeda, Osamu
AU  - Maeda O
AUID- ORCID: 0000-0003-4700-6541
AD  - Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 
      Nagoya, Aichi 466-8560 Japan. ROR: https://ror.org/008zz8m46. GRID: 
      grid.437848.4. ISNI: 0000 0004 0569 8970
FAU - Shimokata, Tomoya
AU  - Shimokata T
AD  - Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 
      Nagoya, Aichi 466-8560 Japan. ROR: https://ror.org/008zz8m46. GRID: 
      grid.437848.4. ISNI: 0000 0004 0569 8970
FAU - Yokota, Kenji
AU  - Yokota K
AD  - Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, 
      Aichi 466-8550 Japan. ROR: https://ror.org/04chrp450. GRID: grid.27476.30. ISNI: 
      0000 0001 0943 978X
FAU - Koike, Hiroshi
AU  - Koike H
AD  - Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, 
      Nagoya, Aichi 466-8550 Japan. ROR: https://ror.org/04chrp450. GRID: 
      grid.27476.30. ISNI: 0000 0001 0943 978X
FAU - Sakai, Tomohisa
AU  - Sakai T
AD  - Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, 
      Nagoya, Aichi 466-8550 Japan. ROR: https://ror.org/04chrp450. GRID: 
      grid.27476.30. ISNI: 0000 0001 0943 978X
FAU - Ikuta, Kunihiro
AU  - Ikuta K
AD  - Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, 
      Nagoya, Aichi 466-8550 Japan. ROR: https://ror.org/04chrp450. GRID: 
      grid.27476.30. ISNI: 0000 0001 0943 978X
FAU - Urakawa, Hiroshi
AU  - Urakawa H
AD  - Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, 
      Nagoya, Aichi 466-8550 Japan. ROR: https://ror.org/04chrp450. GRID: 
      grid.27476.30. ISNI: 0000 0001 0943 978X
FAU - Nishida, Yoshihiro
AU  - Nishida Y
AD  - Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, 
      Nagoya, Aichi 466-8550 Japan. ROR: https://ror.org/04chrp450. GRID: 
      grid.27476.30. ISNI: 0000 0001 0943 978X
AD  - Department of Rehabilitation, Nagoya University Hospital, Nagoya, Aichi 466-8560 
      Japan. ROR: https://ror.org/008zz8m46. GRID: grid.437848.4. ISNI: 0000 0004 0569 
      8970
FAU - Akiyama, Masashi
AU  - Akiyama M
AD  - Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, 
      Aichi 466-8550 Japan. ROR: https://ror.org/04chrp450. GRID: grid.27476.30. ISNI: 
      0000 0001 0943 978X
FAU - Ando, Yuichi
AU  - Ando Y
AD  - Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 
      Nagoya, Aichi 466-8560 Japan. ROR: https://ror.org/008zz8m46. GRID: 
      grid.437848.4. ISNI: 0000 0004 0569 8970
LA  - eng
PT  - Journal Article
DEP - 20231116
PL  - Singapore
TA  - Int Cancer Conf J
JT  - International cancer conference journal
JID - 101734231
PMC - PMC10764704
OTO - NOTNLM
OT  - Drug interactions
OT  - Pazopanib
OT  - Potassium-competitive acid blockers
OT  - Proton pump inhibitors
OT  - Soft tissue sarcoma
COIS- Conflict of interestDr. Ando reports grants and personal fees from Chugai 
      Pharmaceutical Co., Ltd., grants and personal fees from Bayer Holding Ltd., 
      grants from BeiGene, Ltd., and personal fees from Geo Holdings Corporation.
EDAT- 2024/01/08 06:43
MHDA- 2024/01/08 06:44
PMCR- 2024/11/16
CRDT- 2024/01/08 04:36
PHST- 2023/08/28 00:00 [received]
PHST- 2023/10/23 00:00 [accepted]
PHST- 2024/11/16 00:00 [pmc-release]
PHST- 2024/01/08 06:44 [medline]
PHST- 2024/01/08 06:43 [pubmed]
PHST- 2024/01/08 04:36 [entrez]
AID - 638 [pii]
AID - 10.1007/s13691-023-00638-2 [doi]
PST - epublish
SO  - Int Cancer Conf J. 2023 Nov 16;13(1):63-67. doi: 10.1007/s13691-023-00638-2. 
      eCollection 2024 Jan.